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Trachoma is an important cause of blindness. The causative organism is an intracellular bacte-
rium, Chlamydia trachomatis, which is susceptible to single-dose azithromycin [1]. A World
Health Organization (WHO)-led program aims to eliminate trachoma as a public health prob-
lem globally by 2020 [2]. Yaws is a cause of skin, bone, and cartilage disease. The causative
organism is a spirochaete bacterium, Treponema pallidum ssp. pertenue, which is susceptible to
single-dose azithromycin [3]. A WHO-led program aims to eradicate yaws globally by 2020
[4].
These diseases are both found in hard-to-reach populations—they affect the poorest people
living in the most remote areas of the countries where they’re found—and have some apparent
similarity in the methods recommended to counter them. Maximum synergy between pro-
grams is possible only if the two diseases affect the same communities, and if program goals
permit alignment of work. Trachoma’s elimination as a public health problem means “the
reduction of disease incidence, prevalence, morbidity or mortality to a locally acceptable level
as a result of deliberate efforts” [5], whereas yaws eradication requires “permanent reduction to
zero of the worldwide incidence of infection caused by a specific agent as a result of deliberate
efforts” [5]—a quite different goal. This symposium reviews the extent to which the epidemiol-
ogies of and management strategies for these diseases actually overlap, to determine areas for
mutually beneficial collaboration.
Has Global Control of Either Yaws or Trachoma Been Attempted
Previously?
In 1949, the Haiti yaws control program began to employ long-acting penicillin injections, sup-
planting earlier efforts using toxic and poorly efficacious arsenicals. Organized with military-
style intensity, the campaign became a resounding success, prompting the first global commit-
ment to eradicate yaws [6,7]. Over the next several decades, the incidence of yaws declined to
such a level that it was believed to be disappearing altogether; as a consequence, mobile teams
were widely disbanded or repurposed. Recrudescence followed [8]. A second, generally half-
hearted effort to eradicate yaws was initiated in the late 1970s, which was again unsuccessful.
In the 1990s, national elimination programs interrupted transmission in Ecuador and India
[6]. Then, in 2010–2011, a randomised trial conducted in Papua New Guinea demonstrated
that a single oral dose of azithromycin is at least as efficacious as intramuscular penicillin in
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achieving cure [3], stimulating development of a WHO-endorsed strategy [9] for a third
attempt at global yaws eradication.
In the 1950s, several countries launched campaigns attempting to control trachoma using
tetracycline eye ointment [7]. From the recipients’ perspective, ocular tetracycline is not an
ideal therapy: it is difficult to apply, irritant to the conjunctivae, and, for refractive reasons,
blurs vision for a few minutes after application. Prolonged use—six weeks continuous or six
months intermittent treatment—is recommended for cure. Because most individuals provided
with tetracycline ointment are asymptomatic, it is not surprising that results were mixed. It
was soon realised that such campaigns would be resource-intensive and lengthy, yet might not
work. Trachoma, it was decided, was not a suitable disease for control via mass treatment [7].
The 1990s discovery that single-dose azithromycin was at least as effective as a six-week course
of tetracycline eye ointment [10] reignited enthusiasm and led to development of the commu-
nity-based “SAFE” strategy for global elimination, in which mass treatment with antibiotics
(A) is combined with facial cleanliness (F) and environmental improvement (E) to reduce
transmission, with surgery (S) being provided for advanced disease.
How Is the Need for Interventions against These Infections
Determined?
For trachoma, population-based prevalence survey data are important, because the district-
level prevalence in 1- to 9-year-old children of the sign “trachomatous inflammation—follicu-
lar” (TF) [11] is the key index for determining whether or not to implement the A, F, and E
components of SAFE [12]. However, after several years of SAFE implementation, the positive
predictive value of TF for ocular C. trachomatis infection often decreases, at both the individual
and community level. Determining when to stop antibiotic mass distribution may therefore be
problematic; research to address this is underway. For yaws, baseline prevalence estimates are
not necessarily needed because the WHOMorges strategy for eradication is required in any
population in which at least one clinically suspicious case is confirmed serologically to be yaws.
WHO has produced a picture guide [13] to aid clinical diagnosis; a point-of-care antibody test
performs well [14,15], and efforts are in progress to make this test available to programs. Inter-
vention (the WHOMorges strategy [9]) comprises a single round of mass treatment through-
out an endemic focus, followed by surveys every 3 to 6 months to identify and treat individuals
with suggestive skin lesions, plus their contacts. Recently, PCR on swabs of yaws-like, non-gen-
ital skin ulcers of children in Ghana and the Pacific Islands has revealed that 9%–47% contain
DNA of Haemophilus ducreyi, the causative agent of chancroid, without detectable T. pallidum
DNA [16,17], suggesting that PCR may be required for specific post-treatment surveillance.
There is much more to learn about the epidemiology and pathogenesis of yaws and how best to
use diagnostics to guide eradication.
Will Susceptibility of Both Infections to Azithromycin Permit
Mutually Beneficial Collaboration between Mass Treatment
Programs for the Two Diseases?
Both the program to eradicate yaws and the program to eliminate trachoma recommend mass
treatment (treatment of every resident member of a population)—the trachoma program once
annually for up to 5 years (depending on baseline TF prevalence in 1- to 9-year-olds) before an
impact survey, and the yaws program for one round only, followed by intermittent case finding
(Table 1).
Apart from the number of rounds of mass treatment, there are three key differences in the
way each program operationalises azithromycin use. First, for trachoma, the recommended
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dose is 20 mg/kg, to a maximum of 1 g. In yaws, the dose is 30 mg/kg, to a maximum of 2 g.
However, for practical reasons, yaws programs determine dose by age, and trachoma programs
determine dose by height, which probably makes the different dosage recommendations less
programmatically significant than they might first appear. For example, in one setting, because
trachoma’s height-based dosing algorithm is designed primarily to minimise under-dosing, the
mean dose received by children aged 6 months to 9 years was>29 mg/kg [18]. Whether a
lower dose might be effective for yaws, or a higher dose made routine in trachoma programs
operating where yaws is co-endemic, are matters for further study and discussion. This should
not prevent both programs from continuing work for public health benefit whilst develop-
ments are awaited.
Table 1. Key characteristics of trachoma and yaws and their control.
Trachoma Yaws
Causative organism C. trachomatis serovars A, B, Ba, and C T. pallidum ssp. pertenue
Hypothesized routes of transmission Mechanical transfer from infected eyes to uninfected
eyes via ﬁngers, fomites, and ﬂies. No known animal
reservoir.
Mechanical transfer from a primary or secondary yaws
lesion to broken skin of an uninfected individual via
direct contact or, possibly, ﬂies. No known animal
reservoir.
Clinical course Repeated episodes of active (inﬂammatory) trachoma
over many years cause conjunctival scarring, which in
some individuals eventually draws the eyelashes
inward so that they rub on and damage the cornea.
Multiple phases of disease. Primary yaws manifests as a
papilloma at the inoculation site, which then ulcerates
and scars over months. Untreated patients develop
cutaneous, skeletal, and constitutional features of
secondary yaws and, eventually, in some cases, tertiary
yaws, characterized by necrotic and/or hypertrophic
lesions of soft tissue and bone.
Epidemiology Active trachoma is most common in pre-school-age
children, with the prevalence of blinding consequences
increasing with age; even in most hyper-intense
transmission areas, trachomatous blindness is rare
before adulthood.
Primary yaws is most common in school-age children.
Secondary yaws occurs 1 to 24 months after untreated
primary yaws. Tertiary yaws, now rare, occurs 5 or more
years after untreated secondary yaws.
Sub-clinical infection provides a
rationale for mass treatment of
endemic populations
Yes. The proportion of individuals without clinical signs
who have conjunctival C. trachomatis infection varies
with the local intensity of transmission.
Yes. For each clinical case there may be more than ﬁve
infected individuals without signs. Asymptomatic latent
infection may persist for years between secondary and
tertiary yaws.
Program goal Elimination as a public health problem: reduction in the
prevalence of trachomatous trichiasis (TT) unknown to
the health system to <1 per 1,000 total population, and
in the prevalence of TF in 1- to 9-year-olds to <5% in
each district.
Eradication: no serologically positive children <5 years
old and no new cases of active yaws for 3 consecutive
years, in all countries where yaws has ever been known.
Strategy name The “SAFE” strategy: surgery, antibiotics, facial
cleanliness, and environmental improvement.
The WHO Morges strategy.
Recommended antibiotic Azithromycin Azithromycin
Recommended antibiotic dose 20 mg/kg, maximum 1 g 30 mg/kg, maximum 2 g
Recommended antibiotic schedule Annual mass treatment for 3 or 5 years (depending on
baseline prevalence) before re-survey.
One round of mass treatment, then targeted treatment
(of all active clinical cases and their contacts) every 3 to
6 months.
Unit of implementation District (the administrative unit for health care
management, which, for purposes of clariﬁcation,
consists of a population unit between 100,000 and
250,000 persons).
Conforming to the estimated extent of the endemic focus
at baseline, and village- or community-based at follow-
up and during surveillance.
Surveillance Population-based surveys to estimate district-level
prevalences of TT and TF, conducted two years after
an impact assessment has shown that elimination
goals have been reached.
Active surveillance in all villages using village volunteers
and school teachers.
doi:10.1371/journal.pntd.0004071.t001
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Second, in trachoma programs, the recommended intervention unit is the district: a popula-
tion of 100,000 to 250,000 people. For yaws, the recommended intervention unit changes with
time, being flexible at baseline (conforming to the estimated extent of the endemic focus) and
village- or community-based subsequently.
Third, trachoma elimination guidance stresses the importance of adjunctive measures
alongside antibiotic distribution—namely, promotion of facial cleanliness and environmen-
tal improvement—to reduce transmission of ocular C. trachomatis. This multi-pronged
approach implicitly recognizes the very low likelihood that infection will be cleared from a
population through the use of one or several rounds of antibiotic treatment alone, and the
consequent necessity to alter transmission intensity to maximise the impact of mass treat-
ment. Though in cross-sectional data, access to hand-washing facilities is associated with
lower risk of yaws infection [19], the WHOMorges strategy [9] does not explicitly incorpo-
rate hygiene-related interventions, but rather includes them under a general heading of
“health promotion.” Regardless, yaws programs in some countries do recognize their poten-
tial importance [6].
Where Do Trachoma and Yaws Both Occur?
Resolving the complexities of different control strategies for these diseases will only be of prac-
tical relevance (to avoid treatment with doses of azithromycin that may be too low, and to
avoid duplicate treatments by different programs) if there are populations endemic for both.
The priority, therefore, is to delineate overlap. Trachoma is known or suspected to be of public
health significance in 51 countries [20]. Building on two decades of less intensive data gather-
ing, the Global Trachoma Mapping Project is currently working to establish the population-
based prevalence of disease in each suspected endemic district for which accurate data are not
available, as a prelude to implementation of elimination activities wherever required [21]; prev-
alence category data are posted to the open-access Global Atlas of Trachoma (www.
trachomaatlas.org). The spatial distribution of yaws is much less certain. Clinical cases are now
reported from 13WHOmember states, while the status of a further 73 previously endemic
member states is unknown [22]. Work is currently underway to identify which previously
yaws-endemic countries are most likely to still harbour cases of yaws and should be prioritized
for urgent mapping, and which are likely to have achieved local interruption of transmission
and should be targeted for formal certification. The geographic overlap of the two diseases at
country level is shown in Fig 1.
Within endemic countries, the distribution of each disease is heterogeneous. Each “begins
where the road ends,” in hot, tropical settings. But while trachoma is classically found in dry,
dusty areas, yaws is restricted to humid environments, presumably due to the growth require-
ments of the organism.
Available data on the spatial overlap of trachoma (www.trachomaatlas.org) and yaws [23] at
the first sub-national administrative level are shown in Fig 2 for West Africa, and in Fig 3 for
Southeast Asia and the Pacific. Table 2 shows the number and total population of districts
known or suspected to be co-endemic for both diseases; it can be readily appreciated from
these data that the area of potential overlap is far greater than the area for which overlap
has been established. Much more effort is needed to delineate populations in which yaws is
found.
Although the other endemic treponematoses, bejel and pinta, may also overlap geographi-
cally with trachoma and are likely to be responsive to azithromycin, even less is known about
the distribution of these diseases than is known about that of yaws.
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Besides Mass Treatment with Azithromycin, Are There Other
Potential Program Synergies?
Yes. First, as already mentioned, efforts are underway to map the prevalence of trachoma in
every suspected endemic district. Where yaws is or may be co-endemic, it saves money and
time to add collection of yaws data to trachoma mapping fieldwork, as has been done in the
Solomon Islands [19], although the optimal evaluation unit size, sampling fraction, and sam-
pling strategy are yet to be defined for yaws [24]. Regardless, the mapping infrastructure estab-
lished for trachoma should be an asset for the yaws program.
Second, identification of individuals with TT is the first component of trachoma’s SAFE
strategy. This involves screening large numbers of individuals for this potentially blinding
Fig 1. Categorization of endemicity of trachoma and yaws at country level, worldwide, 2013. For the purposes of this figure, a country is categorized as
endemic for a disease based on its status in the Global Health Observatory database (http://www.who.int/gho/en/) as at 15 December 2014. A country is
“endemic for blinding trachoma” in this database if it contains one or more administrative areas in which the most recent population-based prevalence data
held by the Global Atlas of Trachoma (www.trachomaatlas.org) show the prevalence of TF in 1- to 9-year-olds to be10% and/or the prevalence of TT in the
whole population to be0.1%. Papua New Guinea is additionally categorized as “endemic for blinding trachoma” on this map on the basis of preliminary
survey work carried out by the Ministry of Health.
doi:10.1371/journal.pntd.0004071.g001
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condition, which is time-consuming but critical. Simultaneously screening for other endemic
diseases, including yaws, is likely to maximise overall efficiencies for local health systems.
Third, the facial cleanliness and environmental improvement components of the SAFE
strategy require participatory education in endemic communities, plus work to enhance the
delivery of water and appropriate methods for disposal of human faeces. These measures are
intended to reduce transmission of ocular C. trachomatis. Health education designed for tra-
choma control purposes could be expanded to provide a more comprehensive package, includ-
ing, for example, encouraging appropriate ulcer care to limit transmission of T. pallidum ssp.
pertenue. Similarly, improvement in water supplies is likely to also benefit yaws control: good
personal hygiene contributes to reducing infection spread.
Fourth, in the impact assessment and validation of elimination or certification of eradica-
tion stages of each program, in part because of the difficulty in making definitive diagnoses on
clinical grounds, it is possible that serological and/or nucleic acid amplification-based
Fig 2. First-level administrative areas of countries in West and Central Africa co-endemic or potentially co-endemic for trachoma and yaws, based
on reported clinical data on yaws in 2013 [23] and the most recent population-based prevalence data on TF held by the Global Atlas of Trachoma
(www.trachomaatlas.org) as at 15 December 2014.
doi:10.1371/journal.pntd.0004071.g002
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diagnostics will be required (though introducing these things for trachoma would require more
evidence and a change to current guidance [25]). Whilst detection of nucleic acid from the
pathogens of yaws and trachoma may not be perfectly suited to an integrated diagnostic sys-
tem, in part because the samples (conjunctival swab, ulcer swab) are different, multiplex testing
in the serology laboratory can provide data on the presence or absence of antibodies against
multiple antigens from a sample of<1 μL of blood, facilitating use in integrated surveillance of
Fig 3. First-level administrative areas of countries in Southeast Asia and theWestern Pacific co-endemic or potentially co-endemic for trachoma
and yaws, based on reported clinical data on yaws in 2013 [23] and the most recent population-based prevalence data on TF held by the Global
Atlas of Trachoma (www.trachomaatlas.org) as at 15 December 2014.
doi:10.1371/journal.pntd.0004071.g003
Table 2. Active trachoma–yaws co-endemic and potentially co-endemic districts worldwide, 15
December 2014 (number of districts [estimated total population resident in those districts]).
TF = trachomatous inflammation—follicular.
Yaws cases currently reported Yaws previously endemic
TF prevalence in 1- to 9-year-olds 10% 34 [4,928,234] 946 [141,298,660]
Trachoma suspected 27 [7,666,278] 226 [40,465,453]
doi:10.1371/journal.pntd.0004071.t002
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various tropical and waterborne diseases [26]. Antibody-based epidemiological assessment for
yaws and other treponemal diseases has been in place for more than five decades [19,27]. The
concept is presently being evaluated for trachoma, but early work has demonstrated promise,
indicating the potential utility of seroprevalence in young children as an indicator of altered
transmission dynamics in endemic populations [28]. There may ultimately be scope for collab-
oration here, following on from previous successful collaboration in the research setting [19].
Conclusions
The global yaws and trachoma programs have much to learn from each other’s histories, cur-
rent projects, and future plans. Where the two diseases are co-endemic, considerable benefits
may be accrued by each program by exploiting opportunities to work together toward two
important public health goals.
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